ExaMD, a Subsidiary of ExaWizards Group, Partners with EPNextS to Develop Digital Services
– Leveraging Expertise in Drug Development Support for Clinical Research and Development in AI Biomarker-Compatible Solutions –

ExaMD Inc., a fully-owned subsidiary of ExaWizards Inc. (Minato-ku, Tokyo, Representative Director & President: Makoto Haruta, hereinafter ExaWizards) has announced a business alliance with EPNextS, Inc. (Shinjuku-ku, Tokyo; CEO: Tatsuma Nagaoka, hereinafter EPNextS), a subsidiary of EPS Holdings, Inc. EPNextS, which engages in drug development support (CRO) and digital health service development within the group, will combine their expertise with ExaMD to develop digital health services that utilize AI biomarkers.

Purpose of the Partnership
The Japanese medical sector has made little progress in developing AI-powered Software as Medical Devices (SaMD) or health apps based on clinical evidence, even as social demand for such services increases every year. Our goal in partnering with EPNextS is to develop apps and software services that consumers can use with confidence and create new markets in the medical sector and health markets.

Strengths of Both Companies
ExaMD was established as a 100% subsidiary of ExaWizards in February 2024 and inherited their multimodal AI health and medical products and services business. The company is developing their first wave of products, including an SaMD for dementia diagnosis support that uses conversational AI and non-SaMD cognitive function measurement software for the health and medical markets. ExaMD plans to develop new services that utilize AI biomarkers to detect and predict health risks by using multimodal data such as voice and video. The company will also build capabilities for manufacturing, selling, conducting clinical trials, and ensuring communication distribution functions. ExaMD will pursue other partnerships to accelerate development and market entry.

The EPS Group (under parent company EPS Holdings) is comprised of EPNextS (a healthcare solutions provider) and its subsidiary EPS Corporation (EPS), which engages in CRO. As Japan’s largest CRO, EPS provides support for domestic and international clinical trials and system development. EPS actively seeks new healthcare services focusing on pre-disease and preventive care while collaborating across different industries. EPS subsidiary EP Mediate Co., Ltd. supports the rapid market launch of medical devices, in vitro diagnostic drugs, and regenerative medicine products, boasting one of the largest systems in the country for medical device development support.

【Company Overview of EPNextS】
Company Name: EPNextS Co., Ltd.
Location: 2-1 Tsukudo Terrace, Tsukudo Hachiman-cho, Shinjuku-ku, Tokyo
Established: October 2022
CEO: Tatsuma Nagaoka
Business: Healthcare solution provider overseeing CRO, SMO, and CSO businesses
URL: https://www.epnexts.co.jp/

【ExaMD Corporate profile】
Company name: ExaMD Inc.
Location: 4-2-8 Shibaura, Minato-ku, Tokyo, 5F, Sumitomo Realty & Development Mita Twin Building East
Established: February 1, 2024 (scheduled) 
Representative: Koji Hazama, Representative Director
Business: Planning, development, sales, and alliance of products and services using multi-modal AI technology to solve social issues related to healthcare 
URL: https://examd.com/

【ExaWizards Corporate profile】
Company name: ExaWizards Inc.
Location: 4-2-8 Shibaura, Minato-ku, Tokyo, 5F, Sumitomo Realty & Development Mita Twin Building East
Established: February 2016
Representative: Makoto Haruta, Representative Director & President
Business: Industrial innovation and resolution of social issues via AI service development
URL: https://exawizards.com/

＜Media Contact＞
ExaWizards Inc. Public Relations: publicrelations@exwzd.com